NEW YORK, May 18, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) who purchased shares between August 12, 2014 and April 28, 2017. The action, which was filed in the USDC for the Eastern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (2) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
Shareholders have until July 11, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/intra-cellular-therapies-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage
Google Halts UK YouTube TV Measurement Service After Legal Action
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 



